Researchers at EMBL’s European Bioinformatics Institute and the Medical University of Vienna have found evidence that B cells might play an important role in immunotherapy for melanoma.
Currently, immunotherapy is primarily focused on T cells, but the results suggest that B cells could also provide an interesting research avenue.
Immunotherapy is a form of cancer treatment that uses the body’s own immune system to recognise and fight the disease.
It comes in a variety of forms, including cancer vaccines, targeted antibodies or tumour-infecting viruses.
Only some cancer patients currently benefit from this kind of therapy.
In the case of melanoma, which is a particularly aggressive form of skin cancer, established immunotherapies focus on T cells.
T cells play an important role in controlling and shaping the immune system and they are able to directly kill cancer cells, while also recruiting other cells into the process.
A recent study published in Nature Communications has shown that, alongside T cells, B cells play a critical role in triggering melanoma-associated inflammation.
B cells are a type of white blood cell, which can produce antibodies along with several important messenger molecules.
The researchers found that, in the case of melanoma, B cells act almost like a satnav, directing T cells to the tumour via the secretion of such distinct messenger molecules.
“Immunotherapy has transformed cancer treatment,” explains Johannes Griss, Researcher at the Medical University of Vienna and EMBL-EBI.
“It unleashes T cells so they can fight cancer in a more effective way. For the first time, we found that B cells also play an important part in the process and help T cells find the tumour. The role of B cells in immunotherapy is still largely unknown, but it seems they may have more impact than previously thought.”
During the study, the researchers observed that when B cells were depleted from melanoma patients, the number of T cells and other immune cells dramatically decreased within the tumours as well.
In subsequent experiments, the researchers showed that a special subtype of B cells seems to be responsible for guiding T cells and other immune cells to the tumour.
Interestingly, melanoma cells seem to force B cells to develop into this distinct B cell subtype.
Most excitingly, this specific B cell subtype also increased the activating effect of current immune therapies on T cells, and higher numbers of this B cell subtype in tumours before therapy predicted that a patient would respond better to subsequent immunotherapy.
“Further research is required to answer questions such as how melanoma cells modify B cells, what mechanism B cells use to support the activation of T cells, and how we can help these B cells to support current immunotherapies in cancer patients,” concludes Griss.